![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: NIPAL3 |
Gene summary for NIPAL3 |
![]() |
Gene information | Species | Human | Gene symbol | NIPAL3 | Gene ID | 57185 |
Gene name | NIPA like domain containing 3 | |
Gene Alias | DJ462O23.2 | |
Cytomap | 1p36.11 | |
Gene Type | protein-coding | GO ID | GO:0006810 | UniProtAcc | Q6P499 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
57185 | NIPAL3 | ATC12 | Human | Thyroid | ATC | 5.42e-06 | -6.20e-02 | 0.34 |
57185 | NIPAL3 | ATC1 | Human | Thyroid | ATC | 1.38e-08 | 2.87e-01 | 0.2878 |
57185 | NIPAL3 | ATC2 | Human | Thyroid | ATC | 2.25e-04 | 6.50e-01 | 0.34 |
57185 | NIPAL3 | ATC4 | Human | Thyroid | ATC | 6.76e-06 | -3.92e-02 | 0.34 |
57185 | NIPAL3 | ATC5 | Human | Thyroid | ATC | 7.46e-03 | -1.03e-01 | 0.34 |
Page: 1 2 3 4 5 6 |
![]() |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | ![]() |
Colorectum | SER | ![]() |
Colorectum | MSS | ![]() |
Colorectum | MSI-H | ![]() |
Colorectum | FAP | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:1903830 | Colorectum | FAP | magnesium ion transmembrane transport | 7/2622 | 17/18723 | 5.62e-03 | 3.61e-02 | 7 |
GO:0015693 | Colorectum | FAP | magnesium ion transport | 7/2622 | 18/18723 | 8.10e-03 | 4.77e-02 | 7 |
GO:19038301 | Colorectum | CRC | magnesium ion transmembrane transport | 7/2078 | 17/18723 | 1.46e-03 | 1.57e-02 | 7 |
GO:00156931 | Colorectum | CRC | magnesium ion transport | 7/2078 | 18/18723 | 2.16e-03 | 2.11e-02 | 7 |
Page: 1 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
NIPAL3 | SNV | Missense_Mutation | rs150713534 | c.290N>T | p.Ala97Val | p.A97V | Q6P499 | protein_coding | deleterious(0.01) | probably_damaging(0.999) | TCGA-D8-A1JD-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | SD |
NIPAL3 | SNV | Missense_Mutation | c.793C>A | p.Gln265Lys | p.Q265K | Q6P499 | protein_coding | tolerated(1) | benign(0.056) | TCGA-E9-A1NC-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | CR | |
NIPAL3 | SNV | Missense_Mutation | novel | c.680T>C | p.Leu227Pro | p.L227P | Q6P499 | protein_coding | deleterious(0.03) | benign(0.012) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
NIPAL3 | SNV | Missense_Mutation | novel | c.1117G>A | p.Glu373Lys | p.E373K | Q6P499 | protein_coding | tolerated(0.6) | probably_damaging(0.971) | TCGA-VS-A958-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
NIPAL3 | SNV | Missense_Mutation | rs141630558 | c.773N>T | p.Ala258Val | p.A258V | Q6P499 | protein_coding | deleterious(0.01) | benign(0.063) | TCGA-A6-5660-01 | Colorectum | colon adenocarcinoma | Male | >=65 | III/IV | Ancillary | leucovorin | SD |
NIPAL3 | SNV | Missense_Mutation | c.190N>G | p.Ser64Ala | p.S64A | Q6P499 | protein_coding | tolerated(0.56) | benign(0.003) | TCGA-AA-3663-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD | |
NIPAL3 | SNV | Missense_Mutation | rs200419498 | c.109N>A | p.Ala37Thr | p.A37T | Q6P499 | protein_coding | tolerated(0.6) | benign(0.023) | TCGA-AA-3811-01 | Colorectum | colon adenocarcinoma | Female | >=65 | III/IV | Unknown | Unknown | PD |
NIPAL3 | SNV | Missense_Mutation | c.799N>A | p.Tyr267Asn | p.Y267N | Q6P499 | protein_coding | deleterious(0) | probably_damaging(0.985) | TCGA-AA-3811-01 | Colorectum | colon adenocarcinoma | Female | >=65 | III/IV | Unknown | Unknown | PD | |
NIPAL3 | SNV | Missense_Mutation | novel | c.599N>G | p.Asn200Ser | p.N200S | Q6P499 | protein_coding | tolerated(0.06) | benign(0.01) | TCGA-AA-3984-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
NIPAL3 | SNV | Missense_Mutation | c.491N>A | p.Gly164Asp | p.G164D | Q6P499 | protein_coding | deleterious(0) | possibly_damaging(0.812) | TCGA-AD-6895-01 | Colorectum | colon adenocarcinoma | Male | >=65 | III/IV | Unknown | Unknown | SD |
Page: 1 2 3 4 5 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |